Bhat R, Vidyasagar D, Vadapalli M, Whalley C, Fisher E, Hastreiter A, Evans M
J Pediatr. 1979 Aug;95(2):313-6.
Indomethacin is currently used for the pharmacologic closure of PDA in preterm infants with respiratory distress syndrome. However, the response to the drug has been variable and the disposition of the drug in preterm infants is not well understood. We studied the pharmacokinetics of indomethacin in nine preterm infants with birth weights ranging from 800 to 1,960 gm and gestational ages of 28 to 36 weeks. Three different dose schedules (0.1, 0.25, 0.3 mg/kg dose) were used. The plasma half-life of indomethacin ranged from 11 to 20 hours. Peak levels were achieved within four hours and ranged from 0.027 to 0.310 microgram/ml. The half-life in infants less than 32 weeks' gestation was significantly prolonged compared to that in infants greater than 32 weeks. Protein-binding studies with 14C indomethacin showed that 98% of indomethacin was protein bound. Absorption of orally administered indomethacin appears to be poor and incomplete. No immediate major complications could be correlated to indomethacin therapy in this study.
吲哚美辛目前用于患有呼吸窘迫综合征的早产儿动脉导管未闭的药物性闭合。然而，对该药物的反应存在差异，且吲哚美辛在早产儿体内的处置情况尚不清楚。我们研究了9名出生体重在800至1960克之间、胎龄为28至36周的早产儿中吲哚美辛的药代动力学。使用了三种不同的给药方案（剂量分别为0.1、0.25、0.3毫克/千克）。吲哚美辛的血浆半衰期为11至20小时。4小时内达到峰值水平，范围为0.027至0.310微克/毫升。与胎龄大于32周的婴儿相比，胎龄小于32周的婴儿半衰期显著延长。用14C吲哚美辛进行的蛋白结合研究表明，98%的吲哚美辛与蛋白结合。口服吲哚美辛的吸收似乎较差且不完全。在本研究中，没有直接的主要并发症与吲哚美辛治疗相关。
